Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States

References

• Campbell RR, Spehar AM, French DD. Proactive postmarketing surveillance: overview and lessons learned from medication safety research in the veterans health administration. In: Henriksen K, Battles JB, Keyes MA, Grady ML, editors.Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 1: Assessment).Rockville, MD: Agency for Healthcare Research and Quality;2008.
   Google Scholar
• Woosley RL, Rice G. A new system for moving drugs to market. Issues Sci Technol. 2005;21:2.
   Web of Science ®Google Scholar
• Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol. 2016;35:185–198.
   Google Scholar
• Armstrong K. Methods in comparative effectiveness research. J clin oncol. 2012;30(34):4208–4214. doi:10.1200/JCO.2012.42.2659
   PubMed Web of Science ®Google Scholar
• Albert RK. “Lies, damned lies … ” and observational studies in comparative effectiveness research. Am J Respir Crit Care Med. 2013;187(11):1173–1177. doi:10.1164/rccm.201212-2187OE
   PubMed Web of Science ®Google Scholar
• Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report–part I. Value Health. 2009;12(8):1044–1052. doi:10.1111/j.1524-4733.2009.00600.x
   PubMed Web of Science ®Google Scholar
• Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the international society for pharmacoeconomics and outcomes research good research practices for retrospective database analysis task force report–part iI. Value Health. 2009;12(8):1053–1061. doi:10.1111/j.1524-4733.2009.00601.x
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer. J clin Oncol. 2009;27(18suppl):LBA4509. doi:10.1200/jco.2009.27.18s.lba4509
   Google Scholar
• Hess LM, Cinfio FN, Wetmore S, et al. Enhancing the budget impact model for institutional use: a tool with practical applications for the hospital oncology pharmacy. Hosp Pharm. 2016;51(6):452–460. doi:10.1310/hpj5106-452
   Google Scholar
• Results of analyses for chemotherapy administration utilization and chemotherapy drug utilization, 2005–2011 for medicare fee-for-service beneficiaries; 2013. Available from: http://www.siteneutral.com/wp-content/uploads/2016/06/16_Final-Moran-Memo.pdf. Accessed September 23, 2019.
   Google Scholar
• Li Q, Jiang H, Li H, et al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget. 2016;7(31):50656.
   PubMedGoogle Scholar
• Namikawa T, Munekage E, Munekage M, et al. Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. Mol clin Oncol. 2016;5(1):74–78. doi:10.3892/mco.2016.892
   PubMedGoogle Scholar
• Yi JH, Kang JH, Hwang IG, et al. A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: in the perspectives of ethnicity and histology. Cancer Res Treat. 2016;48(2):553–560. doi:10.4143/crt.2015.155
   PubMed Web of Science ®Google Scholar
• Paulson AS, Hess LM, Liepa AM, et al. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer. 2018;21(5):831–844. doi:10.1007/s10120-018-0796-z
   Web of Science ®Google Scholar
• FDA. Orphan drug designations and approvals; 2018. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed Oct 20, 2018.
   Google Scholar
• Ajani JA, Barthel JS, Bekaii-Saab T, et al. Gastric cancer. JNCCN. 2010;8(4):378–409. doi:10.6004/jnccn.2010.0030
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Gravalos C, Marquez A, Garcıa-Carbonero R, et al. Correlation between HER2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symp. 2007;130(Abst):89.
   Google Scholar
• Grillo F, Fassan M, Fiocca R, Mastracci L. Heterogeneous HER2/neu expression in gastric and gastroesophageal cancer. Human Pathol. 2016;48:173–174. doi:10.1016/j.humpath.2015.08.023
   Web of Science ®Google Scholar
• Hess LM, Michael D, Mytelka DS, Beyrer J, Liepa AM, Nicol S. Chemotherapy treatment patterns, costs, and outcomes of patients with gastric cancer in the United States: a retrospective analysis of electronic medical record (EMR) and administrative claims data. Gastric Cancer. 2016;19(2):607–615. doi:10.1007/s10120-015-0486-z
   PubMed Web of Science ®Google Scholar
• Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report–part III. Value Health. 2009;12(8):1062–1073. doi:10.1111/j.1524-4733.2009.00602.x
   PubMed Web of Science ®Google Scholar